BFF MDI 320/9.6 μg
Sponsors
Pearl Therapeutics, Inc., AstraZeneca
Conditions
AsthmaCOPDChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disorder
Phase 2
Phase 3
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)
CompletedNCT02465567
Start: 2015-06-30End: 2019-07-26Updated: 2021-02-02
Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
CompletedNCT02536508
Start: 2015-08-10End: 2017-09-12Updated: 2021-02-26
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
CompletedNCT02766608
Start: 2016-05-31End: 2017-12-01Updated: 2019-09-24
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)
CompletedNCT04609878
Start: 2020-12-15End: 2025-03-21Updated: 2026-06-30
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)
CompletedNCT04609904
Start: 2021-03-01End: 2025-03-20Updated: 2026-07-02
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)
CompletedNCT05202262
Start: 2022-01-12End: 2025-02-26Updated: 2026-01-28
Related Papers
30 more papers not shown